ESR1 and cancer: To explore the therapeutic potential of AMPC-based combinations for the treatment of ER+HER2+ MC cells, the Cambridge Anti-Cancer Compound Library was screened in combination with varying concentrations of AMPC (0, 5, 10, or 20 μM) in MDA-MB-361 and BT474 cells, revealing inhibition of cell viability (Fig. 4A).